| Mrs Melanie Henson Parker, | |
|
28 Colonial Ct, Barboursville, WV 25504-9409 | |
| (251) 610-7886 | |
| Not Available |
| Full Name | Mrs Melanie Henson Parker |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 28 Colonial Ct, Barboursville, West Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831443860 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Melanie Henson Parker, 28 Colonial Ct, Barboursville, WV 25504-9409 Ph: () - | Mrs Melanie Henson Parker, 28 Colonial Ct, Barboursville, WV 25504-9409 Ph: (251) 610-7886 |
News Archive
Johns Hopkins undergraduates have invented a device to improve cell therapy for diabetes patients by anchoring transplanted insulin-producing cells inside a major blood vessel.
An international team of researchers in Mexico and the United States has uncovered a new genetic clue that contributes to an increased risk of developing type 2 diabetes, particularly the elevated risk among Mexican and other Latin American populations.
Alec Murray was 13. He enjoyed camping, fishing and skiing. At home, it was video games, movies and books. Having just completed middle school with "almost straight A's," those grades were going to earn him an iPhone for his upcoming birthday.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it was expanding its Phase 2 clinical trial of STA-9090 in patients with Stage IIIB and Stage IV non-small cell lung cancer (NSCLC) from up to 69 patients to up to 146 patients based on encouraging activity observed in the first stage of the two stage clinical trial.
The kinase IKK phosphorylates the protein mutated in Huntington's disease to promote its removal and neuron survival, but IKK may be a double-edged sword that increases neurotoxicity in later stages of the disease. The study, led by researchers from the University of California, Irvine, will be published online December 21 in the Journal of Cell Biology (www.jcb.org).
› Verified 7 days ago
Madeleine Blake Ray, MS/CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 100 Brady Dr, Barboursville, WV 25504 Phone: 304-972-6140 | |
Mrs. Allison Brooke Kays, M.S., CF, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3427 Us Route 60 East, Barboursville, WV 25504 Phone: 304-736-8255 Fax: 304-736-4851 | |
Ms. Cassie Lake Stroud, M.A., CCC-S Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3427 Us Route 60 East, Barboursville, WV 25504 Phone: 304-736-8255 Fax: 304-736-4851 |